Associated Papers
Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations.
Rodriquenz MG et al.
Cancer Medicine, 2025
Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.
Ko TK et al.
Frontiers in Oncology, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Genetic Characterization of Molecular Targets in Korean Patients with Gastrointestinal Stromal Tumors.
Park J et al.
Journal of Gastric Cancer, 2020
Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors.
Ohshima K et al.
Cancer Science, 2019
31553483 (PubMed )
Supplement: CAS-110-3821-s008.xlsx › Table_S2
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S et al.
Cancer Cell International, 2019
Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.
Lourenço N et al.
Molecular Cancer, 2014
Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.
Bachet JB et al.
Plos One, 2013
Select a paper to view details